Close menu




March 23rd, 2023 | 08:02 CET

BioNxt Solutions, Bayer, BioNTech - These pharma stocks offer growth potential

  • Biotechnology
  • research
  • Pharma
Photo credits: pexels.com

The risk of cancer is increasing worldwide for people over the age of 50. The reasons for this are lack of sleep and exercise, pre-existing diseases and poor nutrition. It has now also been scientifically proven that permanent stress is a cause of Parkinson's disease. According to the WHO, disabilities and deaths due to Parkinson's are increasing faster worldwide than for any other neurological disease. Pharmaceutical and biotech companies are doing everything they can to improve the quality of life of those affected. The Canadian biotech company BioNxt is working on a comparative study to improve a therapy patch for treating Parkinson's and make accompanying drug products scalable. Bayer subsidiary Bluerock Therapeutics is using data from the Apple Watch to research Parkinson's symptoms. And CEO Uğur Şahin of BioNTech has closed a billion-dollar deal in cancer therapy.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: Bionxt Solutions Inc. | CA0909741062 , BAYER AG NA O.N. | DE000BAY0017 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    BioNxt Solutions - Launches comparative trial in Parkinson's therapy

    The week started with a touching birthday video of Bruce Willis surrounded by his family, posted by his ex-wife Demi Moore on Instagram. The actor suffers from a specific form of dementia disease that causes symptoms similar to Parkinson's disease rollingstone.de/frontotemporale-demenz-das-ist-die-krankheit-an-der-bruce-willis-leidet-2556499.

    Parkinson's disease represents a gradual deterioration of the brain, manifested by motor signs such as slowed movements, tremors and balance problems when walking, as well as other complications such as memory loss, pain and muscle weakness. Motor disorders such as uncontrolled tremors negatively impact speech and mobility and immensely affect the quality of life of those affected. Another example of this insidious disease is the affected actor Michael J. Fox, known from the movie "Back to the Future."

    The therapeutic market for Parkinson's disease comprises more than 10 million people worldwide and is growing steadily. The increasing worsening of symptoms and complications leads to a significant reduction in the quality of life of those affected by Parkinson's disease. Many need care, which is an enormous burden for both sufferers and caregivers. This makes it all the more valuable to have an easy-to-use and well-tolerated medication that brings great relief to both sides. A patch impregnated with the active ingredient rotigotine provides an improvement in therapy. The patch is applied to the patient's skin and can thus ensure a 24-hour supply of the active ingredient. The patch, launched by manufacturer TDS in 2007, generated revenues of EUR 348.3 million in 2021 via independent sales.

    BioNxt Solutions Inc. is a biotech accelerator company focused on developing next-generation drug formulations and drug delivery systems, diagnostic screening, and the production and evaluation of new pharmaceutical compounds. Now, BioNxt will enhance the existing patch and make it scalable through related TDS drug products along the customer journey of Parkinson's patient's thanks to its in-house platform technology. To this end, the biotech company is launching a comparative study.

    The global transdermal skin patch market was valued at nearly EUR 6 billion in 2020 and is expected to reach approximately EUR 18.6 billion by 2028. BioNxt's transdermal patch is thus a promising product in a growing market. The Company has now started manufacturing clinical samples for the study planned for the early second quarter of 2023.

    Bayer: Subsidiary researches Parkinson's disease with sensor data

    Bayer subsidiary BlueRock Therapeutics is also getting started with a new study to research Parkinson's disease. To this end, the Company is cooperating with Rune Labs, which specializes in sensor monitoring. Due to the numerous ailments, the multi-layered Parkinson's disease provides biotech and pharmaceutical companies, in particular, the opportunity to develop further drug products and therapies that are a perfect fit.

    "Parkinson's disease is an incredibly complex condition, with symptoms often varying from hour to hour throughout the day," said Seth Ettenberg, president and CEO of BlueRock Therapeutics. "New tools and approaches are needed to reduce the reporting burden of patients in trials and to measure and assess disease progression more effectively."

    The biopharma company will partner with Rune Labs to use the StrivePD tool, which was developed for the Apple Watch and enables data collection and remote monitoring. This uses Apple's Movement Disorder API to capture tremor movements. The FDA-approved app allows patients to document their medication, side effects and other symptoms.

    Bayer faces a leadership change in just a few weeks. Werner Baumann will be succeeded by Bill Anderson. But there is no peace: Critical voices from investors are increasing against the Chairman of the Supervisory Board, Norbert Winkeljohann. Winkeljohann holds too many offices, so how intensively he fulfils his Supervisory Board duties is unclear. After the investment company Union Investment, DWS now also expresses concerns about Winkeljohann's numerous posts.

    BioNTech - Billion dollar deal in the fight against cancer

    BioNTech has expanded its product development in the field of cancer therapies with a new deal. The biotech company has acquired the worldwide rights to a promising cancer immunotherapy from a US company OncoC4 and made an upfront payment of EUR 185.5 million. This move is another milestone in the research and development of innovative cancer therapies. The antibody-based compound ONC-392 aims to enhance immune responses against cancer cells. A Phase I/II study has already generated initial data on the compound's tolerability and efficacy.

    BioNTech and OncoC4 believe that their product candidate represents an optimized version of a CTLA-4 blocker. This variant causes fewer adverse effects in healthy tissues, allowing for broader application.

    "Although CTLA-4 has been known as a promising target for more than a decade, we believe that its full potential in cancer immunotherapy has not yet been realized," said Prof. Dr Uğur Şahin, CEO and Co-Founder of BioNTech. "The data presented by OncoC4 on its ONC-392 antibody indicate a differentiated safety profile and encouraging clinical activity in treating various tumor types. We believe this antibody is a valuable addition to our immuno-oncology portfolio, both as monotherapy and in combination with our personalized immunotherapies."


    There is currently a lot of activity in the pharma and biotech sector thanks to groundbreaking new technologies, as evidenced by BioNTech's deal with US-based OncoC4. The down payment of EUR 185.5 million alone shows the confidence BioNTech founder Şahin sees in this cooperation. Bayer subsidiary BlueRock Therapeutics is also focusing on innovative technologies. With the collaboration with Rune Labs, both companies are using remote sensory monitoring in Parkinson's patients to research the symptoms of tremors for new therapy approaches. Meanwhile, BioNxt Solutions is focusing on the improvement and scalability of existing products in the Parkinson's therapy market. With a comparative study, they are testing the further development of a therapy patch, which has already created an established market.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author



    Related comments:

    Commented by André Will-Laudien on June 21st, 2024 | 07:00 CEST

    Biotech: What counts is selection! Bayer, Vidac Pharma, Formycon, and Evotec in focus

    • Biotechnology
    • Pharma
    • Biotech

    The biotech sector has so far been unable to keep pace with the high-tech-heavy NASDAQ. However, there are now signals from the central banks that a turnaround in interest rates is imminent. This is because, on the one hand, the US economy is weakening, and on the other hand, inflationary pressure appears to be easing. With lower interest rates, life science companies can refinance themselves more cheaply. Due to the different dynamics, it is now important to fish out the pearls. We select attractive entry levels.

    Read

    Commented by Fabian Lorenz on June 18th, 2024 | 06:30 CEST

    Price jump at TUI! Bayer share price slumps! Globex Mining makes millions!

    • Mining
    • Gold
    • Commodities
    • Pharma
    • Travel

    TUI shares were among the day's winners on the German stock market yesterday. The tourism group benefited not only from positive analyst comments but also from the FTI bankruptcy. Can the share now end its months-long sideways movement? There are also good reasons for higher prices at Globex Mining. The mining incubator recently received CAD 3 million from the gold group Agnico Eagle - and that is not the end of the story. The latest analyst comments on Bayer shares are not very promising. Yesterday's DAX share price reaction was correspondingly negative. However, the management was optimistic.

    Read

    Commented by Armin Schulz on June 17th, 2024 | 06:30 CEST

    BioNTech, dynaCERT, Plug Power - A single piece of news can change everything

    • Hydrogen
    • greenhydrogen
    • Biotechnology

    Share prices are characterized by their high volatility and can undergo significant changes in a short space of time. Often, just one piece of company news can completely change investor confidence. Shares that were previously under selling pressure and were avoided can suddenly become very popular and experience considerable price increases. Examples include Lufthansa, whose share price rose significantly with the end of the COVID-19 pandemic. Market sentiment can turn quickly when negative factors disappear. A single piece of positive company news can prompt investors to become more involved again, significantly increasing demand and, consequently, the share price. We have identified three potential turnaround candidates.

    Read